PANTHERx Rare Appoints Bansi Nagji as CEO; Rob Snyder appointed Executive Chair
The PennZone/10277229

Trending...
PITTSBURGH, July 25, 2024 ~ PANTHERx Rare, one of the leading rare disease specialty pharmacies in the nation, has announced the appointment of Bansi Nagji as their new CEO effective August 1, 2024. Mr. Nagji, who has been serving as a member of the company's board of directors, will now take on the additional responsibility of leading PANTHERx Rare as its CEO. This change in leadership comes as Rob Snyder, the current co-founder and CEO, transitions to a full-time role as Executive Chair.

With over 25 years of experience in various leadership roles within the healthcare industry, Mr. Nagji brings a wealth of knowledge and expertise to his new position. He has a strong background in pharma services and supply chain management, healthcare technology, and digital platforms. Throughout his career, he has successfully led high-growth businesses and implemented effective strategies for organic and inorganic growth. Prior to joining PANTHERx Rare as Executive Chair in December 2023, Mr. Nagji served as President of Healthcare at GoodRx Inc., as well as Executive Vice President and Chief Strategy and Business Development Officer at McKesson Corporation. He also has extensive experience serving on the boards of private and public companies such as Change Healthcare, Deloitte, and Parata Systems.

More on The PennZone
Meanwhile, Dr. Snyder's transition to full-time Executive Chair marks a significant milestone for PANTHERx Rare since its founding in 2011. As CEO, he played a crucial role in driving the organization's growth and transformation through various clinical, operational, and business development initiatives that have continued to benefit patients. In his new role as Executive Chair, Dr. Snyder will focus on collaborating with industry partners to ensure that PANTHERx Rare maintains its reputation for providing quality patient access to essential medications.

Expressing his excitement about taking on the role of CEO at PANTHERx Rare, Mr. Nagji said that he was looking forward to leading the company through its next phase of growth. He acknowledged Dr. Snyder's leadership and the significant impact he has had on the organization since its inception. Mr. Nagji also shared his passion for building businesses that help people gain access to critical medications and expressed his eagerness to use his experience to support PANTHERx Rare's mission of helping those living with rare diseases. He also praised the company's patient-centric culture and expressed his desire to continue working closely with Dr. Snyder in his new role as Executive Chair.

More on The PennZone
Dr. Snyder, on the other hand, reflected on PANTHERx Rare's journey so far and their goal of improving every aspect of the patient experience. He expressed his excitement about dedicating his full-time focus to developing innovative access and support services for patients along their health journey. Dr. Snyder also expressed confidence in Mr. Nagji's abilities and was eager to continue working with him as PANTHERx Rare enters its next phase of growth.

These executive appointments are a testament to PANTHERx Rare's commitment to providing expert and empathetic patient care, as well as their strong leadership bench and rapidly growing team of professionals. With Mr. Nagji at the helm, supported by Dr. Snyder in his new role, PANTHERx Rare is poised for continued success in delivering quality care for those living with rare diseases.
Filed Under: Business
Show All News | Report Violation

0 Comments

Latest on The PennZone